# A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

> **NCT01408888** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 29 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** LY2189265
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01408888
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01408888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01408888, "A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01408888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*